tiprankstipranks
H.C. Wainwright keeps Buy on Dyne Therapeutics after data
The Fly

H.C. Wainwright keeps Buy on Dyne Therapeutics after data

H.C. Wainwright keeps a Buy rating on Dyne Therapeutics (DYN) with a $55 price target after the company announced the 6.8 mg/Kg eight week DYNE-101 data along with the strategy to file for an accelerated approval pathway based on the splicing index as the surrogate endpoint. The most important takeaway from the data is that the 6.8 mg/kg eight week dose showed a 33% reduction in DMPK along with a splicing correction of -25%, signifying that splicing correction might have plateaued around 25%-27%, the analyst tells investors in a research note. The firm says the new data on the central nervous system function seems to be encouraging from the platform point of view, showing platforms ability to target CNS specific pathway. Though splicing correction seems to have hit saturation, functional improvement and myotonic dystrophy type 1 literature supports the use of three months splicing index data for accelerated approval pathway, contends H.C. Wainwright.

Stay Ahead of the Market:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles